Zacks Investment Research on MSN

AMGN's Q4 Earnings & Sales Beat Estimates, Obesity Candidate in Focus

Amgen AMGN reported fourth-quarter 2025 adjusted earnings of $5.29 per share, which beat the Zacks Consensus Estimate of ...
BioSpace

Amgen Wants MariTide To Change Obesity Paradigm With Longer Dosing Periods

Amgen believes that it can transcend the expected tradeoff between convenience and efficacy, anticipating that its ...

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

The data on Pfizer's GLP-1 offer early evidence that the injection can be administered less frequently than existing drugs ...

Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline”

Amgen Inc. (NASDAQ:AMGN) is one of the stocks on Jim Cramer’s recent game plan. Cramer said that he heard good things about the company during the JPMorgan Healthcare Conference, as he commented: With ...
Investor's Business Daily on MSN

Dow Jones leader Amgen leads these biotech stocks heading into Q4 earnings season

Dow Jones biotech giant Amgen, along with fellow biotech stocks Gilead and Vertex, are due to report fourth-quarter earnings ...

Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections

The plant will help make Lilly's experimental drug called retatrutide, which has shown the highest weight loss seen to date in a late-stage trial.